Patients with locally advanced liver tumors or invasive parasitic disease have long been considered surgically "unresectable," leaving only oncological or palliative interventions. However, a new review published in Hepatobiliary & Pancreatic Diseases International (DOI: 10.1016/j.hbpd.2024.12.005) details how Chinese surgeons have advanced extracorporeal liver surgery (ELS) to achieve surgical cure for these patients.
Conventional hepatectomy remains the gold standard for many liver tumors, but its limits are clear when tumors invade the hepato-caval confluence or major vessels. Even total vascular exclusion and in-situ hypothermic perfusion may fail to secure radical resections. Allotransplantation offers another route, but donor organ shortages and lifelong immunosuppression make it impractical for many. For patients with advanced alveolar echinococcosis or complex malignancies, transplant options have long been bleak. Thus, there is an urgent need to explore ELS as an efficient solution.
The review, written by a multi-institutional team, describes three major surgical categories: ex-situ liver resection and autotransplantation (ELRA), ante-situm liver resection and autotransplantation (ALRA), and auxiliary partial liver autotransplantation (APLA). Chinese teams pioneered innovations such as the nonuse of veno-venous bypass (NVVB) to stabilize hemodynamics during the anhepatic phase, novel vascular reconstruction strategies to preserve future liver remnant vasculatures, and umbilical vein recanalization to secure portal perfusion. These refinements simplified operations and reduced perioperative risks.
By classifying indications for both liver malignancy and alveolar echinococcosis, surgeons can now better select ideal patients and anticipate outcomes. Clinical data show five-year overall survival rates over 35% for selected liver malignancies and over 80% for alveolar echinococcosis. Precision planning using three-dimensional imaging, functional liver volume equations, and virtual surgery has further boosted predictability and safety. Together, these advances have turned ELS into a representative of the Precision Liver Surgery paradigm, merging radical resection with organ preservation while improving patient safety and long-term survival.
"ELS represents one of the most ambitious frontiers in hepatobiliary practice," said Prof. Jia-Hong Dong, a pioneer in the field. "What was once experimental is now a refined and standardized procedure that can achieve surgical cure for patients previously labeled as inoperable. China's collaborative innovations have changed global perspectives on what is possible in liver surgery."
The impact extends beyond the operating room. By eliminating the need for donor grafts and lifelong immunosuppression, ELS has become a practical lifeline for patients with otherwise untreatable disease. As international centers adopt methods pioneered in China—such as NVVB strategies and innovative autograft reimplantation patterns—the field is poised for broader global uptake. Looking forward, integrating ELS with interventional radiology, systemic therapies, and regenerative medicine could further expand indications and outcomes. Establishing global registries and consensus frameworks will be vital to ensure this now-proven surgery achieves its full potential worldwide.
